CPT code 36522 – Extracorporeal photopheresis

Key takeaways

CPT code 36522 reports one complete extracorporeal photopheresis (ECP) session, covering leukapheresis, photoactivation and reinfusion.

Methoxsalen (UVADEX) is reported separately under a HCPCS drug code and is not bundled into 36522.

Medicare NCD 110.4 covers ECP for cutaneous T-cell lymphoma, refractory chronic GvHD and refractory acute cardiac allograft rejection.

Bronchiolitis obliterans syndrome after lung transplant is covered only inside a CMS-approved clinical study, and every other indication is non-covered.

Most commercial payers require prior authorization for 36522, so a missing or expired authorization is an avoidable denial.

CPT code 36522: Official descriptor and procedure summary

CPT code 36522 describes a single session of extracorporeal photopheresis performed as a complete service. CMS names “36522 – Photopheresis, extracorporeal” as the code for billing ECP in the Medicare Claims Processing Manual. One session covers leukapheresis, photoactivation of the collected cells with psoralen, and reinfusion of the treated leukocytes.

ECP runs on specialized apheresis equipment, with a qualified operator and a treating physician. Each of those elements must be documented for the claim to hold up under payer review.

What CPT 36522 includes and what it does not

The bundle decides what sits on the 36522 claim line and what needs a line of its own.

Bundled within 36522 (do not bill separately)

• Leukapheresis (separation of white blood cells from whole blood)
• Addition of psoralen (methoxsalen/UVADEX) to the collected cells
• UVA irradiation of the psoralen-treated leukocytes
• Reinfusion of the photoactivated cells
• Routine monitoring during the procedure session

Not bundled: bill separately

• Psoralen/UVADEX drug cost: Report it under the applicable HCPCS J-code (see the modifiers and companion codes section below). The drug is never included in CPT 36522.
• IV access placement: If a separate vascular access procedure is performed and documented, bill it with the appropriate code (e.g., 36000 for intravenous cannula insertion).
• Physician E/M visit: A separately identifiable evaluation and management service on the same date may be billed with modifier 25, subject to documentation standards.

Folding the drug into 36522 without a separate J-code is a common ECP billing error. It understates the claim and leaves the drug unpaid.

How ECP is performed and what coders must document

Documentation drives medical necessity. When payers audit a CPT code 36522 claim, they look for five core elements.

1. Patient preparation note: Confirms the indication, any premedication, weight-based parameters used to calculate the volume of cells to be collected, and physician order.
2. Leukapheresis phase: Records the volume processed, collection duration, cell counts, and equipment serial number or identifier.
3. Psoralen addition: Documents the drug name (methoxsalen/UVADEX), dose in milligrams per milliliter of collected cells, lot number, and administration time.
4. UVA irradiation log: Captures irradiation duration, UVA dose (joules per cm²), and equipment settings. Many centers use an integrated ECP machine (e.g., the Therakos CELLEX system). It generates an automatic printout, so attach it to the record.
5. Reinfusion and post-procedure note: Confirms the treated cells were reinfused, notes any adverse events, and records the time the session ended.

A complete superbill documentation record for ECP should contain all five elements. Missing any single element gives a payer a defensible reason to deny the claim as “insufficient documentation of medical necessity.”

Covered indications and paired ICD-10 codes

Every CPT code 36522 claim must include at least one ICD-10-CM diagnosis code that establishes medical necessity. Payers cross-reference the diagnosis against their coverage policy before adjudicating the claim. Full descriptors for each code below are in our ICD-10-CM code library.

NCD 110.4 names what is covered, and every other indication is non-covered. For the cardiac indication, our T86.21 page explains how heart transplant rejection is coded. Commercial payers keep their own lists, so check the policy before treating a Medicare non-covered indication as unpayable.

Medicare coverage rules for CPT code 36522

Medicare coverage for CPT code 36522 is governed by National Coverage Determination 110.4, last revised through CMS decision memo CAG-00324R2. The NCD sorts indications into three tiers.

• Nationally covered: Cutaneous T-cell lymphoma is covered for palliative treatment of skin manifestations that have not responded to other therapy. Chronic GvHD and acute cardiac allograft rejection are covered when refractory to standard immunosuppressive drug treatment. The record must document that failure.
• Clinical study only: Bronchiolitis obliterans syndrome following lung allograft transplantation is covered only within a CMS-approved clinical research study. Any such study had to be approved by April 30, 2014, and the session must take place in a hospital inpatient or outpatient setting.
• Non-covered: Every other indication, including acute GvHD and kidney or liver transplant rejection. Billing 36522 for one of them against Medicare will result in a denial with a CO-50 or CO-57 remark code.

A BOS claim also has to carry its clinical study details. CMS returns it as unprocessable without diagnosis code Z00.6, the Q0 or Q1 modifier and the trial number. Institutional claims also need condition code 30. Set side by side, the three tiers leave little room for interpretation.

The CMS Physician Fee Schedule search tool allows you to look up the current payment rate for 36522 by Medicare Administrative Contractor locality. Facility and non-facility rates differ significantly, so verify the correct setting before submitting.

When Medicare coverage for a session is uncertain, give the patient an Advance Beneficiary Notice (ABN) before treatment and keep the signed copy. Insurance eligibility verification before the first ECP session confirms what the patient’s plan will pay before care starts.

Commercial payer policies and prior authorization

Most commercial payers require prior authorization for CPT code 36522. The authorization process varies by payer, but several elements appear consistently across major carrier policies.

• Documented indication: Clinical notes confirming the diagnosis (ICD-10 code) and that it meets the payer’s definition of medical necessity for ECP.
• Failure of first-line therapy: Evidence that conventional treatments were tried and failed, or are contraindicated. For cGvHD, this typically means documented steroid refractoriness.
• Ordering physician specialty: Many payers require the ordering physician to be a hematologist, oncologist, or transplant specialist for GvHD indications.
• Session frequency: Commercial payers often approve a defined number of sessions (commonly two sessions per week for 8-12 weeks) with re-authorization required for continued treatment.
• Facility capability: Payers may require that the procedure be performed at a facility with an accredited apheresis program.

Payer medical policies are not uniform. Aetna, Cigna, UnitedHealthcare, and regional BCBS plans each maintain separate photopheresis coverage policies with different criteria. Always pull the current policy directly from the payer’s provider portal before submitting a PA request. Meeting medical billing compliance standards means documenting every PA request, approval number, and expiry date in the patient record.

Related apheresis CPT codes and how 36522 differs

Extracorporeal photopheresis sits within the therapeutic apheresis code range (36511-36522). Selecting the wrong code is an audit risk and a denial trigger.

36522 and 36511 are frequently confused because both involve separating leukocytes. The difference is what happens to the cells. 36511 collects and discards white blood cells (leukapheresis for therapeutic reduction), while 36522 collects, photoactivates, and returns them. They describe entirely different procedures with different equipment and clinical goals. Billing 36511 instead of 36522 for an ECP session will result in underpayment and may trigger a documentation request.

Common denial reasons for CPT 36522 and how to prevent them

ECP claims fail for predictable reasons, and each denial pattern maps to a specific fix before resubmission. Structured denial management workflows route every denial to its fix, so a resubmission goes out corrected the first time.

Modifiers and HCPCS companion codes to bill with CPT 36522

Modifier selection and companion code accuracy are OIG audit triggers for apheresis claims. Apply them consistently and document the basis for each.

UVADEX (methoxsalen for extracorporeal use) does not have its own permanent HCPCS J-code as of the current code year. Bill it under J9999 (not otherwise classified, antineoplastic drugs) and attach the invoice price, drug name, NDC, and dose administered. Some MACs require a drug invoice on file. Confirm the current J-code assignment with your MAC’s Local Coverage Article before billing, as CMS periodically assigns specific J-codes for previously unclassified drugs.

Reimbursement rates and fee schedule benchmarks for CPT 36522

CPT code 36522 reimbursement varies by payer, place of service, and geographic locality. Here are the key reference points for benchmarking.

Medicare payment benchmarks

• Physician Fee Schedule (non-facility): The national average non-facility payment for 36522 typically falls in the range of $225-$290 per session. The exact amount varies by Medicare locality; use the CMS PFS lookup tool for your specific locality and the current year rate.
• Hospital Outpatient Prospective Payment System (HOPPS): When billed as an outpatient hospital service, 36522 is grouped into an Ambulatory Payment Classification (APC). The APC rate is typically higher than the PFS non-facility rate and is set annually by CMS.
• Facility vs non-facility: The non-facility rate is paid to a physician performing ECP in an office or independent apheresis center. The facility rate applies when the physician bills for professional services and the hospital bills the technical component separately.

UVADEX (billed separately via J9999) adds significant cost to the per-session charge. Drug invoice pricing and MAC-allowed amounts for J9999 vary. Always verify the allowed amount with the payer before assuming full reimbursement of the drug cost.

Commercial payer rates

Commercial payer rates for 36522 are contract-specific. Many commercial payers reimburse at a multiplier of the Medicare PFS rate (commonly 110-150% for hospital outpatient, lower for physician office settings). Reference your payer contract fee schedule for the contracted rate. If 36522 is not separately listed in the contract, escalate to the payer’s provider relations team to establish an agreed rate before delivering the service.

Verifying the contracted rate before each course of ECP treatment prevents surprise write-offs. Clean claim submission for high-cost apheresis services requires confirming both the authorization and the expected allowed amount before the first session. Use the AAPC CPT code lookup to cross-check the descriptor and work RVU against your fee schedule build.

How Pabau keeps ECP authorizations and claims on track

A course of ECP commonly runs two sessions a week for 8 to 12 weeks, and every session is billed as its own claim. Tracked by hand, the authorization number, its expiry date and the sessions used sit in a spreadsheet beside the billing system. A missed expiry date then surfaces weeks later as a CO-15 denial.

In Pabau’s claims management software, the authorization code, dates and session count sit on the patient’s case, with a warning when one is missing. Claims go out through the Claim.MD clearinghouse, which connects to thousands of US payers.

Eligibility checks and ERA remittances come back to the same record. A session paid as 36511 instead of 36522 shows up when the remittance posts, not at the quarterly reconciliation.

Manage ECP claims and authorizations in one place

Pabau keeps each prior authorization’s code, dates and session count on the patient’s case and sends claims through Claim.MD. Your ECP billing team sees a missing authorization before the payer does.

Book a demo

Conclusion

Most 36522 denials can be prevented before the first session. Check the indication against NCD 110.4, get the authorization, and put the methoxsalen on its own claim line. A BOS patient adds one more question, which is whether an approved study exists to bill under at all.

Medicare’s list is short and fixed, so the coverage answer is clear for every patient. Commercial policies change more often, which makes the authorization record the document to keep current across a course of sessions. Book a demo to see how Pabau tracks authorizations and claims for every ECP session in a course.

Continue your research

Need a clearinghouse that handles high-complexity claims? How the Claim.MD clearinghouse works explains claim routing to thousands of US payers, eligibility checks and ERA reconciliation.

Setting up authorization tracking for a course of ECP? The prior authorization process walks through each step from the request to the approval.

Reconciling a short-paid apheresis claim? Electronic remittance advice explained shows how to read an 835 line by line.

Trying to benchmark your denial rate against industry norms? Revenue cycle management fundamentals covers denial rate benchmarks and RCM metrics for specialty practices.

Frequently asked questions